Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-040788
Filing Date
2025-05-08
Accepted
2025-05-08 06:17:43
Documents
57
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0240586-10q_cadrenal.htm   iXBRL 10-Q 419966
2 CERTIFICATION ea024058601ex31-1_cadrenal.htm EX-31.1 11081
3 CERTIFICATION ea024058601ex31-2_cadrenal.htm EX-31.2 10857
4 CERTIFICATION ea024058601ex32-1_cadrenal.htm EX-32.1 5060
5 CERTIFICATION ea024058601ex32-2_cadrenal.htm EX-32.2 4243
  Complete submission text file 0001213900-25-040788.txt   3609523

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20250331.xsd EX-101.SCH 33250
7 XBRL CALCULATION FILE cvkd-20250331_cal.xml EX-101.CAL 21884
8 XBRL DEFINITION FILE cvkd-20250331_def.xml EX-101.DEF 161584
9 XBRL LABEL FILE cvkd-20250331_lab.xml EX-101.LAB 326066
10 XBRL PRESENTATION FILE cvkd-20250331_pre.xml EX-101.PRE 177823
59 EXTRACTED XBRL INSTANCE DOCUMENT ea0240586-10q_cadrenal_htm.xml XML 353769
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 25923673
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)